Search results for "ARDS"

showing 10 items of 1705 documents

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis

2019

Background Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by a broad range of neoplasms to maintain telomere length, permitting uncontrolled replication during their progression. ALT has been described in different types of sarcoma, but a comprehensive analysis of its clinical significance is still lacking. Therefore, we provide here the first meta-analysis on this topic. Methods We searched SCOPUS and PubMed through July 2018 to identify all studies that investigated the prognostic role of ALT in sarcomas. We considered the risk of death (risk ratio, RR) calculated as the number of death vs. total participants during follow-up in ALT+ versus ALT- pati…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisMesenchymalSurvivalALTlcsh:RC254-282digestive systemRisk Assessmentnot known03 medical and health sciences0302 clinical medicineSurgical oncologyInternal medicineGeneticsmedicineHumansClinical significanceALT; ATR; ATRX; Mesenchymal; Prognosis; Sarcoma; SurvivalProportional Hazards Modelsbusiness.industryHazard ratioSoft tissueTelomere HomeostasisSarcomaMiddle AgedTelomeremedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisSurvival Analysisdigestive system diseases3. Good health030104 developmental biologyATRATRXOncology030220 oncology & carcinogenesisRelative riskMeta-analysisSarcomabusinessResearch ArticleBMC Cancer
researchProduct

Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy

2017

Abstract Purpose: There are conflicting results concerning the prognostic value of the CpG island methylator phenotype (CIMP) in patients with nonmetastatic colon cancer. We studied this phenotype in stage III colon cancer characterized for mismatch repair (MMR), RAS, and BRAF status, and treated with adjuvant FOLFOX-based regimen. Experimental Design: Tumor samples of 1,907 patients enrolled in the PETACC-8 adjuvant phase III trial were analyzed. The method used was methylation-specific PCR, where CIMP+ status was defined by methylation of at least 3 of 5 following genes: IGF2, CACNA1G, NEUROG1, SOCS1, and RUNX3. Association between CIMP status and overall survival (OS), disease-free survi…

0301 basic medicineOncologyMaleCancer ResearchOrganoplatinum CompoundsAdjuvant chemotherapyColorectal cancermedicine.medical_treatmentLeucovorincolon cancer stage iiiKaplan-Meier EstimateDNA Mismatch Repair[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsMethylator phenotypecolorectalCetuximabHematologyMiddle AgedColon cancer stage iiiPrognosisPhenotypeStage III Colon Cancer3. Good healthadjuvant chemotherapyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsoncologyFemaleFluorouracilmedicine.drugmedicine.medical_specialtyphenotype[SDV.CAN]Life Sciences [q-bio]/CancerGastrointestinal tumoursDisease-Free Survivalpatient prognosis03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedNeoplasm StagingChemotherapyCpG Island Methylator Phenotypebusiness.industryProportional hazards modeloxaliplatinCancerDNA Methylationmedicine.diseasedigestive system diseasesOxaliplatin030104 developmental biologyMutationCpG IslandsNeoplasm Recurrence LocalbusinessValue (mathematics)030217 neurology & neurosurgery
researchProduct

Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immuno…

2018

A higher capacity to grow under hypoxic conditions can lead to a more aggressive behavior of tumor cells. Determining tumor activity under hypoxia may identify chronic lymphocytic leukemia (CLL) with aggressive clinical course and predict response to chemo-immunotherapy (CIT). A metabolic score was generated by determining pyruvate kinase and lactate dehydrogenase, key enzymes of glycolysis, ex vivo in primary CLL samples under normoxic and hypoxic conditions. This score was further correlated with clinical endpoints and response to CIT in 96 CLL patients. 45 patients were classified as metabolic high risk (HR), 51 as low risk (LR). Treatment-free survival (TFS) was significantly shorter in…

0301 basic medicineOncologyMaleChronic lymphocytic leukemiaHigh-risklcsh:Medicinechemistry.chemical_compoundRisk FactorsClinical endpointGlycolysisAged 80 and overlcsh:R5-920Hazard ratioGeneral MedicineMiddle AgedPrognosisFemaleImmunotherapymedicine.symptomIGHV@lcsh:Medicine (General)GlycolysisResearch PaperAdultmedicine.medical_specialtyLDHGeneral Biochemistry Genetics and Molecular BiologyDisease-Free Survival03 medical and health sciencesLactate dehydrogenaseInternal medicinemedicineBiomarkers TumorHumansPK M2AgedProportional Hazards Modelsbusiness.industrylcsh:RHypoxia (medical)medicine.diseaseLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyMetabolismchemistryMutationTumor HypoxiabusinessEx vivoCLLEBioMedicine
researchProduct

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue

2018

Abstract Background Gene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of prognostic stromal signatures remains limited. Patients and methods Here, we applied the computational method CIBERSORT to generate a 1028-gene matrix incorporating signatures of 17 immune and stromal cytotypes. Then, we carried out a deconvolution on publicly available GEP data of 482 untreated DLBCLs to reveal associations between clinical outcomes and proportions of putative tumor-infiltrating cell types. Forty-five genes related to peculiar prognostic cytotypes were selected and their expression …

0301 basic medicineOncologyMalePathologyHematologic MalignanciesBiopsyDatasets as TopicPredictive Value of TestDeconvolutionCohort StudiesTranscriptomeAntibodies Monoclonal Murine-Derived0302 clinical medicineprognosticatorsimmune system diseaseshemic and lymphatic diseasesTumor MicroenvironmentCluster Analysisdigital expression analysisRandomized Controlled Trials as TopicParaffin EmbeddingHematology; OncologyHematologyMiddle AgedPrognosisCorrigendaProgression-Free SurvivalAlgorithmOncology030220 oncology & carcinogenesisCell-of-originFemaleLymphoma Large B-Cell DiffuseSurvival AnalysiAlgorithmsHumanAdultmedicine.medical_specialtyStromal cellMicroenvironmentFormalin fixed paraffin embeddedPrognosiReproducibility of ResultDissection (medical)03 medical and health sciencesDigital expression analysiYoung AdultPrognosticatorPredictive Value of TestsFormaldehydeInternal medicinemedicineHumansProgression-free survivalGeneSurvival analysisAgedTumor microenvironmentCluster AnalysiProportional hazards modelbusiness.industryGene Expression ProfilingReproducibility of ResultsComputational BiologyOriginal Articlesmedicine.diseaseSurvival AnalysisGene expression profiling030104 developmental biologyDLBCLCohort StudieTranscriptomebusinessDiffuse large B-cell lymphomaDLBCL microenvironment deconvolution cell-of-origin digital expression analysis prognosticators
researchProduct

Prognostic impact and implications of extra-capsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis.

2015

The extranodal extension (ENE) of nodal metastasis (i.e. the extension of tumor cells through the nodal capsule into the perinodal adipose tissue) has recently emerged as an important prognostic factor in different types of malignancies. However, the tumor-node-metastasis (TNM) staging system for colorectal cancer does not consider it as a prognostic parameter. Therefore, we conducted a systematic review and meta-analysis to determine the prognostic role of ENE in patients with lymph node-positive colorectal cancer.Two independent authors searched PubMed and SCOPUS until 7 January 2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects wit…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerExtra-capsular extensionColon cancer; ENE; Extra-capsular extension; Extra-nodal extension; Lymph node metastasis; Rectal cancer03 medical and health sciences0302 clinical medicinecolon cancer; extracapsular extension; extranodal extension; lymph node metastasis; rectal cancerInternal medicineHumansMedicineextracapsular extensionRectal cancerProspective cohort studyLymph nodeProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelHazard ratioCancerextranodal extensionHematologyPrognosismedicine.diseaseColon cancerTreatment Outcome030104 developmental biologymedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisMeta-analysisENEextranodal extension extracapsular extension lymph node metastasis colon cancer rectal cancerRegression AnalysisT-stageExtra-nodal extensionLymph NodesNeoplasm Recurrence LocalColorectal Neoplasmsbusiness
researchProduct

2019

Background Body fat and/or muscle composition influences prognosis in several cancer types. For advanced gastric and gastroesophageal junction cancer, we investigated which body composition parameters carry prognostic information beyond well-established clinical parameters using robust model selection strategy such that parameters identified can be expected to generalize and to be reproducible beyond our particular data set. Then we modelled how differences in these parameters translate into survival outcomes. Methods Fat and muscle parameters were measured on baseline computed tomography scans in 761 patients with advanced gastric or gastroesophageal junction cancer from the phase III EXPA…

0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisProportional hazards modelbusiness.industryModel selectionCancermedicine.diseaseCorrelation03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisPhysiology (medical)SarcopeniaInternal medicineCohortmedicineOrthopedics and Sports MedicinebusinessSurvival analysisJournal of Cachexia, Sarcopenia and Muscle
researchProduct

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value

2017

[EN] Background: The average five-year survival for non-small cell lung cancer (NSCLC) patients is approximately 15%. Emerging evidence indicates that microRNAs (miRNAs) constitute a new class of gene regulators in humans that may play an important role in tumorigenesis. Hence, there is growing interest in studying their role as possible new biomarkers whose expression is aberrant in cancer. Therefore, in this study we identified dysregulated miRNAs by next generation sequencing (NGS) and analyzed their prognostic value. Methods: Sequencing by oligo ligation detection technology was used to identify dysregulated miRNAs in a training cohort comprising paired tumor/normal tissue samples (N = …

0301 basic medicineOncologymedicine.medical_specialtyPathologyBIOLOGIA CELULARNSCLCDNA sequencing03 medical and health sciences0302 clinical medicineInternal medicineMedicineLung cancerValenciaSurvival analysisbiologybusiness.industryProportional hazards modelProfilingExperimental validationbiology.organism_classificationmedicine.diseasePrognosismicroRNAsMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisNGSNon small cellPersonalized medicineprognosisprofilingbusinessResearch Paper
researchProduct

Prognostic Significance of Focal Adhesion Kinase in Node-Negative Breast Cancer.

2017

<b><i>Background:</i></b> Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays an important role as a mediator of cell migration, invasion, proliferation and survival. Conflicting results for the prognostic role of FAK in breast cancer (BC) prompted us to determine its impact. <b><i>Methods:</i></b> Patients with node-negative BC entered this retrospective study. FAK expression was determined by immunohistochemistry (n = 335). The prognostic impact of FAK was examined with Cox regression analyses and Kaplan-Meier estimation in the whole cohort as well as in different molecular subtypes. <b><i>Results:</i>&l…

0301 basic medicineOncologymedicine.medical_specialtyUnivariate analysisProportional hazards modelbusiness.industryHazard ratioRetrospective cohort studymedicine.diseaseConfidence intervalFocal adhesion03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicinemedicineImmunohistochemistrySurgeryOriginal ArticlebusinessBreast care (Basel, Switzerland)
researchProduct

PBRM1 loss is a late event during the development of cholangiocarcinoma

2017

Aims: Somatic mutations in genes encoding chromatin remodellers have been reported recently in several cancer types, including approximately half of cholangiocarcinomas. One of the most commonly mutated chromatin remodellers in cholangiocarcinoma is the Polybromo-1 (PBRM1) gene located on chromosome 3p21, which encodes a subunit of the SWI/SNF complex. The aim of this study was to determine the timing of PBRM1 mutations in biliary carcinogenesis. Methods and results: In order to accomplish this goal, we used immunohistochemistry to assess PBRM1 protein expression in a series of precursor lesions and invasive biliary carcinomas. Previous studies have correlated loss of protein expression on …

0301 basic medicinePathologymedicine.medical_specialtyHistologyBilIN; PBRM1; biliary dysplasia; cholangiocarcinoma; chromatin remodellingchromatin remodellingKaplan-Meier EstimateBiologymedicine.disease_causeArticleBilIN; PBRM1; biliary dysplasia; cholangiocarcinoma; chromatin remodelingChromatin remodelingchromatin remodelingPathology and Forensic MedicinePBRM1PBRM103 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansBilinIntrahepatic CholangiocarcinomaProportional Hazards ModelsBilINMutationNuclear ProteinsCancerGeneral MedicinePrognosismedicine.diseaseChromatinDNA-Binding Proteinsbiliary dysplasiaCell Transformation Neoplastic030104 developmental biologyBile Duct Neoplasmschemistry030220 oncology & carcinogenesisMutationCarcinogenesischolangiocarcinomaTranscription Factors
researchProduct

Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease.

2015

Background: Intention of the study is to assess the cardiovascular mortality of patients with coronary artery disease (CAD) with the biomarkers of angiogenesis PlGF and its endogenous inhibitor sFlt-1. Methods: The cohort included n = 1848 patients with CAD and 282 subjects without CAD. In 85 patients cardiovascular mortality, as combination of fatal myocardial infarction or any cardiac death, during a median follow-up duration of 3.9 years was reported. Results: In Kaplan–Meier curve analysis PlGF in rising thirds was not predictive regarding outcome (p = 0.54), the same was shown for sFlt-1 (p = 0.44). Cox regression for the fully adjusted model provided a hazard ratio (HR) of 0.8 (p = 0…

0301 basic medicinePlacental growth factorMalemedicine.medical_specialtyClinical BiochemistryCoronary Artery DiseaseKaplan-Meier Estimate030204 cardiovascular system & hematologyPregnancy ProteinsCoronary artery disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoveryNatriuretic Peptide BrainmedicineHumansMyocardial infarctionPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1Proportional hazards modelbusiness.industryBiochemistry (medical)Hazard ratioMiddle Agedmedicine.diseasePrognosisPeptide FragmentsVascular endothelial growth factor030104 developmental biologyEndocrinologychemistryCohortCardiologyFemalebusinessSoluble fms-like tyrosine kinase-1Follow-Up StudiesBiomarkers in medicine
researchProduct